Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
Over the last 12 months, insiders at Gain Therapeutics, Inc. have bought $115,770 and sold $5,057 worth of Gain Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Gain Therapeutics, Inc. have bought $97,592 and sold $5,057 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Riley Jeffrey Scott (director) — $115,770.
The last purchase of 30,000 shares for transaction amount of $115,770 was made by Riley Jeffrey Scott (director) on 2024‑03‑28.
2024-03-28 | Riley Jeffrey Scott | director | 30,000 0.1501% | $3.86 | $115,770 | -30.37% | ||
2023-12-21 | Sale | Alder Matthias | Chief Executive Officer | 206 0.0014% | $2.46 | $507 | +36.49% | |
2023-12-07 | Sale | Alder Matthias | Chief Executive Officer | 1,820 0.0122% | $2.50 | $4,550 | +32.16% | |
2022-05-25 | RICHMAN ERIC I | CHIEF EXECUTIVE OFFICER | 2,482 0.0203% | $2.58 | $6,404 | +43.21% | ||
2022-05-19 | RICHMAN ERIC I | CHIEF EXECUTIVE OFFICER | 9,256 0.0816% | $2.83 | $26,194 | +39.63% | ||
2022-05-19 | Calabrese Salvatore | CHIEF FINANCIAL OFFICER | 3,000 0.0252% | $2.70 | $8,100 | +39.63% | ||
2021-08-16 | RICHMAN ERIC I | Chief Executive Officer | 4,922 0.042% | $7.87 | $38,716 | -45.68% |
Riley Jeffrey Scott | director | 30000 0.185% | $1.27 | 1 | 0 | |
Alder Matthias | Chief Executive Officer | 5286 0.0258% | $1.27 | 0 | 2 | |
RICHMAN ERIC I | CHIEF EXECUTIVE OFFICER | 217729 1.0644% | $1.27 | 3 | 0 | +12.38% |
Calabrese Salvatore | CHIEF FINANCIAL OFFICER | 3000 0.0147% | $1.27 | 1 | 0 | +39.63% |
Raymond James Associates | $980,272.00 | 1.44 | 260,019 | +993.07% | +$890,591.21 | <0.01 | |
Royal Bank of Canada | $937,000.00 | 1.38 | 248,500 | +24.1% | +$181,940.14 | <0.0001 | |
Geode Capital Management | $667,734.00 | 0.98 | 177,091 | +16.91% | +$96,583.15 | <0.0001 | |
The Vanguard Group | $450,003.00 | 0.66 | 119,364 | +35.05% | +$116,791.02 | <0.0001 | |
Cm Management Llc | $339,300.00 | 0.5 | 90,000 | 0% | +$0 | 0.02 | |
BlackRock | $284,251.00 | 0.42 | 75,398 | +173.07% | +$180,157.33 | <0.0001 | |
Renaissance Technologies | $176,000.00 | 0.26 | 46,700 | +9.11% | +$14,698.07 | <0.0001 | |
Northern Trust | $175,253.00 | 0.26 | 46,486 | +6.83% | +$11,208.26 | <0.0001 | |
Millennium Management LLC | $167,448.00 | 0.25 | 44,416 | +247.98% | +$119,327.81 | <0.0001 | |
Susquehanna International Group | $162,344.00 | 0.24 | 43,062 | +24.82% | +$32,278.79 | <0.0001 | |
Prelude Capital | $135,041.00 | 0.2 | 35,820 | -38.35% | -$83,995.35 | 0.01 | |
State Street | $116,255.00 | 0.17 | 30,837 | New | +$116,255.00 | <0.0001 | |
Bridgeway Capital Management | $113,100.00 | 0.17 | 30,000 | -34.92% | -$60,697.00 | <0.01 | |
Simplex Trading Llc | $67,000.00 | 0.1 | 17,983 | New | +$67,000.00 | <0.01 | |
UBS | $32,697.00 | 0.05 | 8,673 | -38.15% | -$20,169.37 | <0.0001 | |
Tower Research Capital | $17,463.00 | 0.03 | 4,632 | -5.32% | -$980.22 | <0.0001 | |
Citadel Advisors LLC | $15,921.00 | 0.02 | 4,223 | -93.54% | -$230,618.87 | <0.0001 | |
Wells Fargo | $14,161.00 | 0.02 | 3,756 | +0.78% | +$109.34 | <0.0001 | |
Bank of America | $12,724.00 | 0.02 | 3,375 | New | +$12,724.00 | <0.0001 | |
Morgan Stanley | $10,556.00 | 0.02 | 2,800 | 0% | +$0 | <0.0001 | |
Group One Trading | $7,544.00 | 0.01 | 2,001 | -49.17% | -$7,298.94 | <0.0001 | |
Citigroup | $2,579.00 | <0.01 | 684 | New | +$2,579.00 | <0.0001 | |
Newedge Advisors Llc | $848.00 | <0.01 | 225 | New | +$848.00 | <0.0001 |